<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="220137">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218062</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09262-12</org_study_id>
    <secondary_id>P50DA009262-12</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218062</nct_id>
  </id_info>
  <brief_title>Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals</brief_title>
  <official_title>Pharmacotherapy Dosing Regimen (Cocaine Dependence Population)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine dependence is a major public health problem; an effective primary treatment for
      cocaine dependent individuals has yet to be found. The purpose of this study is to examine
      the effects of d-amphetamine and modafinil, when given alone and in combination, in treating
      cocaine dependent individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine is a strong central nervous system stimulant that is widely abused throughout the
      United Sates. Due to its widespread use, it is important to develop an effective treatment
      for cocaine dependence. Modafinil is a glutamate-enhancing agent. D-amphetamine is a central
      nervous system stimulant that is approved to treat individuals with narcolepsy and attention
      deficit disorder. Both modafinil and d-amphetamine may be effective treatments for cocaine
      dependence. The purpose of this study is to examine the effectiveness of modafinil and
      d-amphetamine, alone and in combination, in treating cocaine dependent individuals.

      This study will last 16 weeks. Participants will be randomly assigned to one of four groups:
      1) 200 mg dose of modafinil; 2) 400 mg dose of modafinil; 3) 30 mg dose of d-amphetamine
      combined with 200 mg dose of modafinil; and 4) placebo. All participants will receive 200 mg
      of modafinil over 4 days. Participants assigned to the 400 mg modafinil treatment group will
      then receive double the initial dose of modafinil for the duration of the study.
      Participants in the combined group (modafinil and d-amphetamine) will receive 15 and then 30
      mg of d-amphetamine over 4 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Substance use</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medication side effects</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil 200mg/ D-Amphetamine 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextro amphetamine sulfate and Modafinil</intervention_name>
    <description>d-amphetamine 30mg / modafinil 200mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>10 day medication run-up of modafinil from 0-200mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 400 mg</intervention_name>
    <description>10 day run up to 400mg of modafinil</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets SCID criteria for cocaine abuse or dependence

          -  In general good health. Individuals who are HIV-positive will not be excluded if in
             good general health, unless medication interactions exist.

        Exclusion Criteria:

          -  Meets diagnostic criteria for psychiatric disorders, including other forms of drug
             dependence, other than nicotine

          -  Current cardiovascular disease, as determined by an electrocardiogram

          -  On probation or parole if the circumstances do not allow study completion or if
             ethical constraints of supervision do not allow confidentiality

          -  Previously received treatment with d-amphetamine, modafinil, or aripiprazole

          -  Currently receiving prescribed medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy M. Schmitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trc.uth.tmc.edu</url>
    <description>Click here for more information about the Treatment Research Clinic at the University of Texas Health Center at Houston</description>
  </link>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 2, 2012</lastchanged_date>
  <firstreceived_date>September 16, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Joy Schmitz</investigator_full_name>
    <investigator_title>Professor - PSY-Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
